NDAORALCAPSULEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVDELZI (seladelpar lysine) is an oral small-molecule drug approved by the FDA on August 14, 2024, for a rare liver disease indication. The mechanism of action and specific indication are not detailed in available data, but the drug represents Gilead Sciences' entry into a specialized hepatic market. Patient monitoring focuses on liver enzyme changes and pruritus management.
Growth11.3 years to LOE
Early-stage commercial trajectory with zero detected competitive pressure suggests potential market opportunity for field and marketing teams to establish market presence.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIVDELZI represents a rare opportunity to join a commercial team launching into an uncontested market with 8+ years of exclusivity. Career growth potential is high for roles focused on market development, specialist field teams, and payer relationships in rare liver disease.
Brand ManagerProduct Manager
Worked on LIVDELZI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.